These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11365719)

  • 21. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 23. An evaluation of drug cocktail combinations for their immunological value in preventing/remitting opportunistic infections.
    Konlee M
    Posit Health News; 1998; (No 16):2-4. PubMed ID: 11365016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinations of protease inhibitors.
    TreatmentUpdate; 1998 Apr; 10(2):1-3. PubMed ID: 11365433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined protease results continue to hold up.
    McGuire S
    Posit Aware; 1997; 8(1):15. PubMed ID: 11364089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage therapy in HIV-positive patients with a previous therapeutic experience with protease inhibitors. Members of the Master Group.
    Maggiolo F; Maserati R; Pan A; Castelli F; Suter F
    AIDS; 1999 Aug; 13(12):1591-2. PubMed ID: 10465091
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
    Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
    Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case studies on treatment.
    Sirinek M
    Posit Aware; 1999; 10(2):29-30. PubMed ID: 11366846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 31. Protease inhibitors: resistance, resistance, resistance.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-HIV therapy update.
    Proj Inf Perspect; 2001 Mar; (32):4-6. PubMed ID: 11682776
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral update.
    Proj Inf Perspect; 1998 Apr; (24):4-5. PubMed ID: 11365718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AIDS therapy. Failure isn't what it used to be...but neither is success.
    Cohen J
    Science; 1998 Feb; 279(5354):1133-4. PubMed ID: 9508685
    [No Abstract]   [Full Text] [Related]  

  • 37. New triple combo trial opens.
    Vazquez E; Whitfield L
    Posit Aware; 1997; 8(6):12. PubMed ID: 11364852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual protease inhibitor therapy.
    HIV Hotline; 1998 Mar; 8(1):12. PubMed ID: 11365354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.